Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Carew

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
Blood Advances|October 27, 2020
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapyShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Irish Journal of Medical Science|December 19, 2007
Stroke unit care: recurrence, mortality and institutionalisation rates-a four year follow-up studyT Walsh, T Donnelly, S Carew, et al.
Journal of the American College of Cardiology|June 13, 2020
Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular OutcomesAllie S Carew, Andrew P Levy, Henry N Ginsberg, et al.
Leukemia|July 30, 2003
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implicationsJ S Carew, Y Zhou, M Albitar, et al.
British Journal of Cancer|April 30, 2009
Targeting HSP90 for cancer therapyD Mahalingam, R Swords, J S Carew, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2025
Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating agingAlexis B Cruickshank-Taylor, Jacob S Kozora, Jennifer S Carew, et al.
Cancer Research|July 20, 2007
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levelsSteffan T Nawrocki, Jennifer S Carew, Leslie Douglas, et al.
Cancers|January 11, 2024
Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?Vanessa Ogbuji, Irasema C Paster, Alejandro Recio-Boiles, et al.
Molecular Cancer Therapeutics|March 27, 2015
Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of TemsirolimusJennifer S Carew, Claudia M Espitia, Weiguo Zhao, et al.
CJC Open|July 22, 2022
Eating Timing and Frequency as a Predictor of Hospitalization and/or Mortality From Coronary Artery Disease: The Linked CCHS-DAD-CMDB 2004-2013 StudyAllie S Carew, Rania A Mekary, Susan Kirkland, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
Blood Advances|October 27, 2020
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapyShariful Islam, Claudia M Espitia, Daniel O Persky, et al.
Irish Journal of Medical Science|December 19, 2007
Stroke unit care: recurrence, mortality and institutionalisation rates-a four year follow-up studyT Walsh, T Donnelly, S Carew, et al.
Journal of the American College of Cardiology|June 13, 2020
Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular OutcomesAllie S Carew, Andrew P Levy, Henry N Ginsberg, et al.
Leukemia|July 30, 2003
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implicationsJ S Carew, Y Zhou, M Albitar, et al.
British Journal of Cancer|April 30, 2009
Targeting HSP90 for cancer therapyD Mahalingam, R Swords, J S Carew, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2025
Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating agingAlexis B Cruickshank-Taylor, Jacob S Kozora, Jennifer S Carew, et al.
Cancer Research|July 20, 2007
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levelsSteffan T Nawrocki, Jennifer S Carew, Leslie Douglas, et al.
Cancers|January 11, 2024
Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?Vanessa Ogbuji, Irasema C Paster, Alejandro Recio-Boiles, et al.
Molecular Cancer Therapeutics|March 27, 2015
Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of TemsirolimusJennifer S Carew, Claudia M Espitia, Weiguo Zhao, et al.
CJC Open|July 22, 2022
Eating Timing and Frequency as a Predictor of Hospitalization and/or Mortality From Coronary Artery Disease: The Linked CCHS-DAD-CMDB 2004-2013 StudyAllie S Carew, Rania A Mekary, Susan Kirkland, et al.
Pageof 11